Pancreatic cancer (PC) is the fourth leading cause of cancer related deaths in the U.S., with a less than 6% fiveyear
survival rate. Treatment is confounded by advanced stage of disease at presentation, frequent metastasis to distant organs
at the time of diagnosis and resistance to conventional chemotherapy. In addition, the molecular pathogenesis of the
disease is unclear. The extensive study of miRNAs over the past several years has revealed that miRNAs are frequently
de-regulated in pancreatic cancer and contribute to the pathogenesis and aggressiveness of the disease. Several studies
have tackled the practical difficulties in the application of miRNAs as viable therapeutic and diagnostic tools. Given that a
single miRNA can affect a myriad of cellular processes, successful targeting of miRNAs as therapeutic agents could likely
yield dramatic results. The current review attempts to summarize the advances in the field and assesses the prospects for
miRNA profiling and targeting in aiding PC treatment.
Keywords: MiRNA, therapy, pancreatic cancer.
Rights & PermissionsPrintExport